Court Clears Biocytogen’s RenNano ® in Landmark Patent Dispute Against Harbour

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315) today announced that it has received a first-instance civil judgment from the Shanghai Intellectual Property Court. The court ruled that Biocytogen did not infringe the relevant patent rights asserted by the plaintiff, Harbour Antibodies BV ("Harbour"), and ordered the plaintiff to bear the litigation costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629347368/en/

The judgment marks a significant first-instance outcome in the litigation and further affirms the independent innovation and intellectual property compliance of Biocytogen's core technology platforms. It also provides greater clarity for existing and prospective partners evaluating the RenNano® platform, reinforcing confidence in the Company's technology platforms and long-term innovation capabilities.

The lawsuit was brought by Harbour in connection with a Chinese invention patent (Patent No. ZL201210057668.0) for which Harbour holds an exclusive license. Harbour had alleged that Biocytogen's RenNano® platform and certain antibody products generated using the platform infringed the asserted Chinese patent rights.

Biocytogen has always been committed to driving innovative drug discovery through proprietary technologies. The Company has established globally competitive technology platforms spanning gene editing, target-humanized animal models, and fully human antibody discovery, supporting its preclinical products and services business as well as its drug development efforts.

As a key component of Biocytogen's antibody discovery capabilities, the RenNano® platform continues to support global collaborations and the discovery of next generation VHH therapeutics.

Biocytogen believes that intellectual property protection is fundamental to advancing innovation in the biopharmaceutical industry. The Company places strong emphasis on the creation, protection, and compliant management of intellectual property while respecting the legitimate intellectual property rights of others.

This favorable first-instance judgment further underscores the originality and independence of Biocytogen's proprietary technologies and reinforces global confidence in the Company's technology platforms and research and development capabilities.

Looking ahead, Biocytogen will continue to drive independent innovation, strengthen its research and development capabilities, enhance its technology platforms, and create greater value for partners worldwide.

About Biocytogen

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260629347368/en/